Barrington Research Expects Reduced Earnings for OPKO Health

Key Points

• Barrington Research has cut its Q3 2025 EPS estimate for OPKO Health from ($0.04) to ($0.06), while maintaining an "Outperform" rating with a price target of $2.25.
• In its latest quarterly results, OPKO Health reported an EPS of ($0.19), missing estimates by ($0.07) and experiencing a 13.9% drop in revenue year-over-year.
• OPKO Health currently has a consensus rating of "Moderate Buy" with an average price target of $2.75.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at Barrington Research reduced their Q3 2025 earnings per share (EPS) estimates for shares of OPKO Health in a report issued on Monday, August 4th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will post earnings of ($0.06) per share for the quarter, down from their previous estimate of ($0.04). Barrington Research has a "Outperform" rating and a $2.25 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. Barrington Research also issued estimates for OPKO Health's Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. During the same quarter last year, the firm posted ($0.01) EPS. The business's revenue was down 13.9% on a year-over-year basis.

OPK has been the topic of several other research reports. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating on the stock. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $2.75.

OPKO Health Price Performance

Shares of OPK stock traded up $0.02 during trading hours on Wednesday, reaching $1.25. 3,543,196 shares of the company were exchanged, compared to its average volume of 2,999,738. The company has a market cap of $992.23 million, a price-to-earnings ratio of -5.00 and a beta of 1.19. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The stock's fifty day moving average is $1.33 and its two-hundred day moving average is $1.47.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $891,000.00. Following the completion of the purchase, the chief executive officer owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 49.69% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OPKO Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Oak Thistle LLC acquired a new stake in OPKO Health in the first quarter valued at approximately $26,000. GM Advisory Group LLC bought a new stake in OPKO Health in the 1st quarter valued at about $33,000. Cerity Partners LLC bought a new stake in OPKO Health during the 1st quarter valued at $36,000. Pallas Capital Advisors LLC bought a new stake in OPKO Health during the 1st quarter worth approximately $43,000. Finally, Voleon Capital Management LP bought a new position in OPKO Health in the 1st quarter worth about $45,000. Institutional investors and hedge funds own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.